Summary
The clinical effectiveness of rifabutin for prophylaxis of disseminated Mycobacterium avium complex infection has recently been demonstrated in HIV-positive patients with low CD4 counts. Rifabutin is a newly marketed, semisynthetic antimycobacterial agent similar to rifampicin (rifampin) in structure and activity. However, rifabutin has important pharmacokinetic differences compared with rifampicin.
Rifabutin has relatively low oral bioavailability; about 20% after single dose administration. With long term administration rifabutin induces its own metabolism and the metabolism of some other drugs. The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (>9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.
In vitro rifabutin is more active against M. avium-intracellulare complex and at least as active against M. tuberculosis as rifampicin. In vivo the advantage of rifabutin is less apparent due to its lower plasma concentrations at equivalent doses. Adverse effects are unusual at the recommended oral dosage of 300 mg/day, but become common as the total daily dose approaches 1g. Dose-limiting toxicity consists of a polyarthralgia/arthritis syndrome, possibly complicated by uveitis. More clinical studies are needed to establish the role of rifabutin in combination therapy for M. avium-intracellulare complex and other mycobacterial infections.
Similar content being viewed by others
References
Marsili L, Pasqualucci CR, Vigevani A, et al. New rifamycins modified at positions 3 and 4: synthesis, structure and biological evaluations. J Antibiot (Tokyo) 1981; 34: 1033–8
Biagi GL, Barbaro AM, Gamba MF, et al. Partition data of penicillins determined by means of reversed-phase thin layer chromatography. J Chromatogr 1969; 41: 371–9
Battaglia R, Pianezzola E, Salgarollo G, et al. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J Antimicrob Chemother 1990; 26: 813–22
Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991; 8: 1434–40
Van der Auwera P, Scorneaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother 1985; 28: 440–1
Woodley CL, Kilburn JO. Determination of in vitro susceptibility of Mycobacterium avium complex strains and Mycobacterium tuberculosis to a spiropiperidyl rifampicin. Am Rev Respir Dis 1982; 126: 586–7
Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis 1985; 132: 710–1
Delia Bruna C, Jabes D, Rossi R, et al. Mycobacterium tuberculosis (MTB): natural resistance and effect of prolonged exposure to rifabutin (RBT) and rifampicin (RMP) [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin: 1993; 1: 332
Wynne B, Delia Bruna C, Imondi A, et al. M. avium complex (MAC); low frequency of natural resistance and absence of selection for resistant bacilli with rifabutin [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin: 1993; 1: 332
Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177–82
Pretet S, Lebeaut A, Parrot R, et al. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 1992; 5: 680–4
Davis Jr CE, Carpenter JL, Trevino S, et al. In vitro susceptibility of Mycobacterium avium complex to antibacterial agents. Diag Microbiol Infect Dis 1987; 8: 149–55
Cynamon MH. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob Agents Chemother 1985; 28: 440–1
Heifets LB, Iseman MD, Lindholm-Levy PJ, et al. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother 1985; 28: 570–5
Mascellino MT, Iona E, Fattorini L, et al. In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare: complex strains isolated from AIDS patients. J Chemother 1991; 3: 357–62
Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988; 137: 719–21
Yajko DM, Nassos PS, Hadley WK. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 117–20
Hawkins CC, Gold JW, Whimbey E, et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184–8
Perumal VK, Gangadharam PR, Iseman MD. Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages. Am Rev Respir Dis 1987; 136: 334–7
Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle 1988; 69: 187–92
Yajko DM, Nassos PS, Sanders CA, et al. Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774. Am Rev Respir Dis 1989; 140: 1198–203
Perronne C, Gikas A, Truffot-Pernot C, et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 34: 1508–11
Gevaudan MJ, Bollet C, Mallet MN, et al. Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum [in French]. Pathol Biol 1991; 39: 436–41
Ungheri D, Sanfilippo A. Activity of LM427 on Legionella spp: in vitro study and intracellular killing. In: Ishigami J, editor. Recent advances in chemotherapy — antimicrobial. Section 3. Tokyo: University of Tokyo Press, 1985: 919–20
Perumal VK, Gangadharam PR, Heifets LB, et al. Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on Mycobacterium intracellulare. Am Rev Respir 1985; 132: 1278–80
Ungheri D, Franceschi G, Delia Bruna C. Main human urinary metabolites of spiropiperidyl rifamycin LM 427: isolation and biological properties. In: Ishigami J, editor. Proceedings of the 14th International Congress of Chemotherapy; Tokyo: University of Tokyo Press, 1985; 3: 1917–8
Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33: 1237–41
O’Brien RJ, Lyle MA, Snider Jr DE. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987; 9: 519–30
Hoffner SE, Hjelm U, Kallenius G. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother 1993; 37: 1285–8
Hjelm U, Kaustova J, Kubin M, et al. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Eur J Clin Microbiol Infect Dis 1992; 11: 51–4
Gevaudan MJ, Bollet C, Mallet MN, et al. Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi [in French]. Pathol Biol 1992; 40: 443–9
Kent RJ, Bakhtiar M, Shanson DC. The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare. J Antimicrob Chemother 1992; 30: 643–50
Klemens SP, DeStefano MS, Cynamon MH. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413–7
Ruf B, Schurmann D, Mauch H, et al. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection 1992; 20: 267–72
Chiodini RJ. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis. J Antimicrob Chemother 1991; 27: 171–6
Klemens SP, Cynamon MH. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 1991; 35: 2026–30
Dautzenberg B, Truffot C, Mignon A, et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d’Etude et de Traitement des Infections a Mycobacteries Resistantes. Tubercle 1991; 72: 168–75
Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828–33
Schoenfelder J, Souder D, Smith J, et al. Rifabutin treatment for bacteremia due to Mycobacterium avium complex (MAC) in patients who received rifabutin or placebo in the MAC prevention studies 023 and 027 [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993: 1: 341
Von Reyn CF, Brown ST, Arbeit RD. Rifabutin prophylaxis against Mycobacterium avium complex infection [letter]. N Engl J Med 1994; 330: 437
O’Brien RJ, Geiter LJ, Lyle MA. Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990; 141: 821–6
Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992; 73: 33–8
Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992; 11: 901–7
Mancini P, Pasqua F, Mazzei L, et al. Rifabutin treatment for tuberculosis patients with liver function abnormalities [letter]. J Antimicrob Chemother 1992; 30: 242
Gillespie SH, Baskerville AJ, Davidson RN, et al. The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection [letter]. J Antimicrob Chemother 1990; 25: 490–1
Zaugg M, Salfinger M, Opravil M, et al. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis 1993; 16: 540–9
Nathan V, Mehta JB, Dralle W. Rifabutin in the treatment of cavitary lung disease due to Mycobacterium gordonae. South Med J 1993; 86: 839–41
Yoder LJ, Jacobson RR, Hastings RC. The activity of rifabutin against Mycobacterium leprae. Lepr Rev 1991; 62: 280–7
Riva M, Crippa S, Di Palma F, et al. Disseminated tuberculosis of the central nervous system responsive to rifabutin. Ital J Neurol Sci 1990; 11: 163–9
Weiser B, Burger H, Eilbott DJ, et al. Efficacy of rifabutin in the treatment of AIDS-related complex. AIDS 1989; 3: 823–7
Torseth J, Bhatia G, Harkonen S, et al. Evaluation of the antiviral effect of rifabutin in AIDS-related complex. J Infect Dis 1989; 159: 1115–8
Mauch H, Reichert B, Ruf B, et al. Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations [in German]. Pneumologie 1990; 44 Suppl 1: 504–6
Yamamoto T, Amitani R, Kuze F, et al. In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex [in Japanese]. Kekkaku 1990; 65: 805–10
Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992; 52: 335–41
Mandell GL, Sande MA. Drugs used in the chemotherapy of tuberculosis and leprosy. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1150
Rifabutin [editorial]. Med Let Drugs Ther 1993; 35: 36–8
Strolin Benedetti M, Efthymiopoulos C, Sassella D, et al. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20: 1113–9
Cocchiara G, Strolin Benedetti M, Vicario GP, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989; 19: 769–80
Vigevani A, Ballabio M, Gioia B, et al. Identification of urinary metabolites of rifamycin LM 427 in man. J Antibiot 1985; 38: 1799–802
Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990; 4: 433–41
Levin RH, Bolinger AM. Treatment of nontuberculous mycobacterial infections in pediatric patients. Clin Pharm 1988; 7: 545–51
Lewis L, Jacobsen F, Mueller B, et al. A phase I/II assessment of oral rifabutin suspension for the prophylaxis of Mycobacterium avium complex in HIV-infected children [abstract]. Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 107
Oesch F, Arand M, Strolin Benedetti M, et al. Inducing properties of rifabutin and rifampicin for selected drug metabolizing enzymes in female rat liver [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 328
Perucca E, Grimaldi R, Frigo GM, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988; 34: 595–9
Breda M, Pianezzola E, Strolin Benedetti M, et al. A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers. Drug Metabol Drug Interact 1992; 10: 323–40
Loos U, Musch E, Jensen JC, et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 63: 1205–11
Benedetti MS, Edwards DM, Pogessi I, et al. Pharmacokinetics of rifabutin in hepatic insufficiency [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 501
Narang PK, Schoenfelder J, Bianchine JR. Impact of altered rifabutin disposition in renal disease on its safety in AIDS patients (CD4 < 200/µL). AIDS 1992; 6 (Suppl. 1): 90
Sale M, Narang PK. Population based assessment of rifabutin and alkaline phosphatase effect on zidovudine disposition in AIDS patients [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 505
Sahai J, Foss N, Li R, et al. The effect of rifabutin (R) on didanosine (ddI) pharmacokinetics [abstract]. In: Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 135
Vandevelde C, Chang A, Andrews D, et al. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991; 11: 88–9
DATRI 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis: evidence for a drug interaction [abstract]. Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 106
Sawyer RC, Brown LS, Narang PK, et al. Evaluation of a possible pharmacologic interaction between rifabutin (RIF) and methadone (MET) in HIV (+) injecting drug users (IDUs) [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 501
Trapnell CB, Narang PK, Li R, et al. Fluconazole (FLU) increases rifabutin (RIF) absorption in HIV (+) patients on stable zidovudine (ZDV) therapy [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 504
Narang PK, Trapnell CB, Schoenfelder JR, et al. Fluconazole and enhanced effect of rifabutin prophylaxis [letter]. N Engl J Med 1994; 18: 1316–7
Fuller JD, Stanfield LED, Craven DE. Rifabutin prophylaxis and uveitis [letter]. N Engl J Med 1994; 330: 1315–6
Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Int Med 1994; 121: 510–2
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skinner, M.H., Blaschke, T.F. Clinical Pharmacokinetics of Rifabutin. Clin. Pharmacokinet. 28, 115–125 (1995). https://doi.org/10.2165/00003088-199528020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199528020-00003